A2M and non-small cell lung carcinoma: To investigate serum APPs as predictive biomarkers for the immunotherapy response, levels of nine APPs (ACT, SAA, AGP, HP, AAT, CRP, A2M, CP and ALB) were measured in 139 patients with NSCLC prior to anti-PD-1 or anti-PD-L1 therapy (Table 1 and Table S1).